Cover Image
市場調查報告書

移植診斷:技術和全球市場

Transplant Diagnostics: Technologies and Global Markets

出版商 BCC Research 商品編碼 379860
出版日期 內容資訊 英文 186 Pages
訂單完成後即時交付
價格
Back to Top
移植診斷:技術和全球市場 Transplant Diagnostics: Technologies and Global Markets
出版日期: 2016年10月27日 內容資訊: 英文 186 Pages
簡介

全球移植診斷市場規模2015年達5億1230萬美金,預計從2016年到2021年以9.8%的年複合成長率 (CAGR) 擴大。

本報告提供全球移植診斷市場相關調查分析,全球市場概要,市場趨勢分析,各用途、終端用戶、地區的分析,生物標記、生物印刷、類器官的新、未來的方法評估,市場動態分析,主要企業簡介,及專利分析等相關的系統性資訊。

第1章 簡介

第2章 摘要整理

第3章 全球移植診斷市場概要

  • 全球移植診斷市場概要
  • 移植診斷的HLA型檢測
  • 市場發展、創新
  • 次世代定序
  • HLA型檢測的政府法規指南
  • HLA型檢測的醫生會、醫學會
  • 影響統計、發病率、罹患率,及市場成長的其他參數
  • 臨床指南、醫療費償付情形
  • 技術趨勢
  • 市場動態

第4章 移植診斷市場分析:各技術

  • 分子化驗技術
  • PCR型分子化驗
  • 定序型分子化驗
  • 非分子化驗技術
  • 血清學化驗
  • 淋巴球混合培養化驗

第5章 各零件

  • 設備

第6章 移植診斷市場分析:各終端用戶

  • 醫院、移植中心
  • 研究實驗室、大學機關
  • 民間服務供應商

第7章 移植診斷市場分析:各應用領域

  • 研究
  • 輸血、骨髓移植計劃

第8章 競爭情形

  • 競爭情形
  • 產品認證、銷售
  • M&A
  • 協定,合作及合作
  • 擴大
  • 投資

第9章 地區分析

  • 北美
  • 歐洲
  • 西班牙
  • 義大利
  • 土耳其
  • 亞太地區
  • 馬來西亞
  • 紐西蘭
  • 其他
  • 巴西
  • 以色列
  • 伊朗
  • 沙烏地阿拉伯

第10章 專利分析

  • 簡介
  • 美國
  • 中國
  • 歐洲

第11章 企業簡介

  • ABBOTT LABORATORIES
  • AFFYMETRIX INC.
  • ASTELLAS PHARMA INC.
  • BIO-RAD LABORATORIES
  • CAREDX INC.
  • DIASORIN S.P.A.
  • F. HOFFMANN-LA ROCHE AG
  • FUJIREBIO EUROPE N.V.
  • ILLUMINA INC.
  • IMMUCOR INC.
  • LINKAGE BIOSCIENCES
  • LUMINEX CORP.
  • OLERUP SSP AB
  • OMIXON BIOCOMPUTING LTD.
  • SIGMA-ALDRICH CORP.
  • THERMO FISHER SCIENTIFIC INC.
  • TRANSPLANT GENOMICS INC.

第12章 附錄

圖表

目錄
Product Code: HLC193A

REPORT HIGHLIGHTS

The global transplant diagnostics market was valued at $512.3 million in 2015 and is estimated to grow at a CAGR of 9.8% from 2016 through 2021.

This report provides:

  • An overview of the global markets for transplant diagnostics.
  • Analyses of global market trends, with data from 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021.
  • Breakdowns of the market by application, end-users, and geography.
  • A look at how factors such as the high cost of instruments and limited insurance and reimbursement coverage available for transplant processes are expected to hamper the growth of the global transplant diagnostics market.
  • Evaluation of novel, future approaches in terms of biomarkers, bio-printing, and organoids.
  • Analyses of the market's dynamics: Drivers, restraints, opportunities.
  • Profiles of major players in the field.

SCOPE OF REPORT

The report covers the current market scenario for transplant diagnostics tests commercially available. These diagnostics tests are extensively used to study the compatibility between the donor and recipient in the process of organ transplantation. The report covers the segments mentioned below based on the revenue generated from the sales of transplant diagnostics products and services. The following need to be taken into consideration:
  • The report considers the revenue generated by the sales of products, services and software used while conducting the transplant diagnostics test. These products can be kits, reagents, devices and software tools, among others.
  • The report considers revenue generated by pre-transplant as well as post-transplant tests.
  • The report does not consider the revenue generated by carrying out blood tests prior to transplant procedures (which is minor and done along with counseling itself).
  • Although the report is closely associated with the organ transplant market, it does not consider any organ transplant cost in any manner. It only considers diagnostics.
  • The periodic tests conducted post-transplant to determine the organ health in recipients' bodies form a significant part of the revenue in the market.

The global transplant diagnostics market is segmented into two classes: nonmolecular assay and molecular assay technologies. Nonmolecular assay technologies are further segmented into serological assay and mixed lymphocyte culture (MLC) assay. The molecular assay technology market is segmented into polymerase chain reaction (PCR)-based and sequencing-based. The global transplant diagnostics technology market is further segmented on the basis of components for in-depth analysis of the market during the analysis period (2015-2021). The market study is detailed for the transplant diagnostics market based on end users as well as application area.

In-depth analysis of these segments is discussed in this report. The report also provides a detailed qualitative account of the market dynamics, technology trends, key strategies and regulatory scenario.

The market is segmented by region into North America, Europe, Asia-Pacific and ROW, including further division into key countries. Companies profiled in this report include Abbott Laboratories Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Illumina Inc., Immucor Inc., Linkage Biosciences, Olerup SSP AB, Qiagen N.V., Thermo Fisher Scientific Inc. and Sigma-Aldrich, among others.

ANALYST'S CREDENTIALS

Yojana Jeevane has more than four years of experience in market intelligence and business research. She has experience in the healthcare domain with respect to medical devices, life sciences and chemicals. She has frequently delivered research services that contain strategic recommendations and top business strategies to help market players develop beneficial strategies. Yojana holds a MBA degree in marketing.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY AND OBJECTIVE
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • SOURCE OF INFORMATION AND METHODOLOGY
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - EXECUTIVE SUMMARY

  • EXECUTIVE SUMMARY
  • SUMMARY TABLE GLOBAL MARKET FOR TRANSPLANT DIAGNOSTICS BY REGION, THROUGH 2021 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL MARKET FOR TRANSPLANT DIAGNOSTICS BY REGION, 2015-2021 ($ MILLIONS)

CHAPTER 3 - GLOBAL TRANSPLANT DIAGNOSTICS MARKET OVERVIEW

  • GLOBAL TRANSPLANT DIAGNOSTICS MARKET OVERVIEW
    • TABLE 1: TYPES OF ORGAN REJECTION POST-TRANSPLANT PROCEDURES
  • HLA TYPING IN TRANSPLANT DIAGNOSTICS
    • TABLE 2: MAJOR TYPES OF HUMAN LEUKOCYTE ANTIGEN
    • TABLE 3: LIST OF AUTOIMMUNE DISEASES LINKED WITH HLA TYPES
    • TABLE 4: LIST OF FEW HLA TESTS COMMERCIALLY AVAILABLE WITH CLINICAL APPLICATIONS
  • MARKET EVOLUTION AND INNOVATIONS
  • NEXT-GENERATION SEQUENCING
    • PREPARATION OF LIBRARY
    • GENERATION OF CLUSTER
    • SEQUENCING OF THE FRAGMENTS
    • ANALYSIS OF THE DATA
    • GOVERNMENT REGULATIONS, MEDICAL ASSOCIATIONS, FOOD AND DRUG ADMINISTRATION AND INTERNATIONAL REGULATORY AGENCIES
  • GOVERNMENT REGULATORY GUIDELINES FOR HLA TYPING
  • MEDICAL ASSOCIATIONS AND SOCIETIES FOR HLA TYPING
    • ROLE OF FDA IN TRANSPLANT DIAGNOSTICS
      • Laboratory-Developed Tests (LDTS)
      • Nucleic Acid-Based Tests
        • TABLE 5: NUCLEIC ACID TESTS APPROVED BY FDA
  • DEMOGRAPHICS, INCIDENCE AND PREVALENCE RATES AND OTHER PARAMETERS INFLUENCING MARKET GROWTH
    • NORTH AMERICA
      • FIGURE 1: NUMBER OF KIDNEY TRANSPLANTS IN NORTH AMERICA BY COUNTRY, 2015
      • FIGURE 2: NUMBER OF LIVER TRANSPLANTS IN NORTH AMERICA BY COUNTRY, 2015
      • FIGURE 3: NUMBER OF ORGAN DONATIONS IN NORTH AMERICA BY TYPE OF DONOR, 2015
      • FIGURE 4: NUMBER OF TRANSPLANTS BY TYPE OF ORGAN IN U.S., JANUARY 1988-JUNE 2016
      • FIGURE 5: TRANSPLANT PROCEDURES PERFORMED BY ORGAN TYPE IN U.S., JANUARY 1988-JUNE 2016 (%)
      • FIGURE 6: NUMBER OF TRANSPLANTS BY AGE OF RECIPIENT IN U.S., JANUARY 1988-JUNE 2016
      • FIGURE 7: NUMBER OF TRANSPLANTS BY TYPE OF DONOR IN U.S., 2011-2015
    • U.S. TRANSPLANT PROCEDURES
      • FIGURE 8: NUMBER OF ORGAN DONATIONS IN U.S. BY TYPE OF DONOR, 2015
      • FIGURE 9: NUMBER OF ORGAN TRANSPLANT PROCEDURES IN U.S. BY TYPE OF ORGAN, 2015
    • CANADA TRANSPLANT PROCEDURES
      • FIGURE 10: NUMBER OF ORGAN DONATIONS IN CANADA BY TYPE OF DONOR, 2015
      • FIGURE 11: NUMBER OF ORGAN TRANSPLANT PROCEDURES IN CANADA BY TYPE OF ORGAN, 2015
    • MEXICO TRANSPLANT PROCEDURES
      • FIGURE 12: NUMBER OF ORGAN DONATIONS IN MEXICO BY TYPE OF DONOR, 2015
      • FIGURE 13: NUMBER OF ORGAN TRANSPLANT PROCEDURES IN MEXICO BY TYPE OF ORGAN, 2015
    • EUROPE
      • FIGURE 14: NUMBER OF KIDNEY TRANSPLANTS IN EUROPE BY COUNTRY, 2015
      • FIGURE 15: NUMBER OF LIVER TRANSPLANTS IN EUROPE BY COUNTRY, 2015
      • FIGURE 16: NUMBER OF ORGAN DONATIONS IN EUROPE BY TYPE OF DONOR, 2015
      • FIGURE 17: HYPERTENSIVE DISEASES IN EUROPE BY COUNTRY, 2015 (%)
      • FIGURE 18: NUMBER OF DEATHS CAUSED BY CIRCULATORY SYSTEM DISEASES IN EUROPE BY COUNTRY, 2012 (%)
      • FIGURE 19: NUMBER OF ORGAN DONATIONS BY TYPE OF DONOR IN EUROPE (FRANCE, GERMANY AND UNITED KINGDOM), JANUARY 1988-JUNE 2016
      • FIGURE 20: NUMBER OF TRANSPLANT PROCEDURES BY TYPE OF ORGAN IN EUROPE (FRANCE, GERMANY AND UNITED KINGDOM), JANUARY 1988-JUNE 2016
    • ASIA-PACIFIC
      • FIGURE 21: NUMBER OF KIDNEY TRANSPLANTS IN ASIA-PACIFIC BY COUNTRY, 2015
      • FIGURE 22: NUMBER OF LIVER TRANSPLANTS IN ASIA-PACIFIC BY COUNTRY, 2015
      • FIGURE 23: NUMBER OF LIVER TRANSPLANTS IN ASIA-PACIFIC BY COUNTRY AND TYPE OF DONOR, 2015
      • China's Transplant Procedures
        • FIGURE 24: NUMBER OF ORGAN/TISSUE TRANSPLANT PROCEDURES BY TYPE OF DONOR IN HONG KONG, 2015
      • Japan Transplant Procedures
        • FIGURE 25: NUMBER OF ORGAN TRANSPLANTS FROM DECEASED DONORS BY TYPE OF ORGAN IN JAPAN, 2015
      • Australia Transplant Procedures
        • FIGURE 26: NUMBER OF ORGAN DONATIONS BY TYPE OF DONOR IN AUSTRALIA, 2015
        • FIGURE 27: NUMBER OF ORGAN TRANSPLANTS BY TYPE OF ORGAN IN AUSTRALIA, 2015
        • FIGURE 28: NUMBER OF TISSUE TRANSPLANT PROCEDURES BY TYPE OF TISSUE IN AUSTRALIA, 2015
      • India Transplant Procedures
    • ROW
  • CLINICAL GUIDELINES AND REIMBURSEMENT SCENARIO
    • GUIDELINES FOR TRANSPLANT DIAGNOSTICS
    • REIMBURSEMENT SCENARIO FOR TRANSPLANT DIAGNOSTICS
      • TABLE 6: LIST OF CPT CODES FOR HLA TYPING WITH SEROLOGICAL TESTING
      • TABLE 7: MAXIMUM FEES FOR PATHOLOGY LABORATORY, ON AND AFTER JANUARY 1, 2015 ($)
  • TECHNOLOGY TRENDS
    • NOVEL INNOVATIONS FOR FUTURE OF TRANSPLANT DIAGNOSTICS
      • Biomarkers
        • TABLE 8: LABORATORY-BASED PRE-TRANSPLANTATION BIOMARKERS
        • TABLE 9: LABORATORY-BASED POST-TRANSPLANTATION BIOMARKERS (ACUTE ALLOGRAFT REJECTION)
        • TABLE 10: LABORATORY-BASED POST-TRANSPLANTATION BIOMARKERS (CHRONIC ALLOGRAFT DAMAGE)
        • TABLE 11: LABORATORY-BASED POST-TRANSPLANTATION BIOMARKERS (ALLOGRAFT ACCOMMODATION)
        • TABLE 12: FDA-APPROVED BIOMARKERS
      • Bioprinting
        • TABLE 13: MATERIALS USED FOR BIOPRINTING
      • Organoids
        • TABLE 14: APPLICATION OF ORGANOIDS BY TYPE
      • Organoids in Transplant Diagnostics
    • U.S. HIV ORGAN POLICY EQUITY (HOPE) ACT, 2013
      • FIGURE 29: HISTORY OF THE HOPE ACT, 2013
    • ELIGIBILITY CRITERIA FOR HIV-POSITIVE DONORS AND RECIPIENTS
      • Eligibility Criteria for HIV-Positive Living Donors
      • Eligibility Criteria for HIV-Positive Deceased Donors
      • Eligibility Criteria for HIV-Positive Recipients
      • Transplant Hospital Criteria
      • Independent Advocates for HIV-Positive Living Organ Donor and Recipient
      • Responsibilities of the Independent HIV-Positive Recipient Advocate
      • Responsibilities of the Independent HIV-Positive Donor Advocate
      • Bio Specimens
    • KEY STRATEGIES
      • FIGURE 30: MAJOR STRATEGIES ADOPTED BY PLAYERS IN THE TRANSPLANT DIAGNOSTICS MARKET
      • TABLE 15: STRATEGIC DEVELOPMENT IN TRANSPLANT DIAGNOSTICS MARKET, 2012-2016 (NO./%)
      • TABLE 16: FDA APPROVALS FOR TRANSPLANT DIAGNOSTICS PRODUCTS, 2013-2016
      • TABLE 17: CE APPROVALS FOR TRANSPLANT DIAGNOSTICS PRODUCTS, 2013-2016
      • TABLE 18: NEW PRODUCT LAUNCHES IN TRANSPLANT DIAGNOSTICS MARKET, 2013-2016
      • TABLE 19: COMPANIES ADOPTING M &A AS A DEVELOPMENTAL STRATEGY IN TRANSPLANT DIAGNOSTICS MARKET
      • TABLE 20: MERGERS AND ACQUISITIONS IN THE TRANSPLANT DIAGNOSTICS MARKET, 2012-2016
      • TABLE 21: COMPANIES ADOPTING AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS AS A DEVELOPMENTAL STRATEGY IN TRANSPLANT DIAGNOSTICS MARKET, 2012-2016
      • TABLE 22: LIST OF COMPANIES THAT ADOPTED AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS AS KEY STRATEGY, 2012-2016
      • TABLE 23: COMPANIES ADOPTING EXPANSION AS A KEY STRATEGY IN TRANSPLANT DIAGNOSTICS MARKET, 2011-2016
      • TABLE 24: COMPANIES ADOPTING INVESTMENT AS A KEY STRATEGY IN TRANSPLANT DIAGNOSTICS MARKET, 2013-2016
  • MARKET DYNAMICS
    • DRIVERS
      • Increasing Geriatric Population
        • FIGURE 31: GLOBAL POPULATION AGED 60 AND OVER BY REGION, 2015 (NO.)
      • Rising Chronic Diseases
        • TABLE 25: CHRONIC DISEASES LISTED BY THE WHO, 2010-2013
      • Increased Research and Development
        • TABLE 26: PRODUCT LAUNCHES IN TRANSPLANT DIAGNOSTICS MARKET, 2012-2016
    • RESTRAINTS
      • Challenges in HLA Sequencing
      • Demand and Supply Gap
        • FIGURE 32: WAITING LIST FOR ORGANS IN U.S. BY TYPE OF ORGAN AS OF JULY 15, 2016 (NO.)
        • FIGURE 33: WAITING LIST FOR ORGANS IN U.S. BY AGE OF DONOR AS OF JULY 15, 2016 (NO.)
    • OPPORTUNITIES
      • Increasing Need for Organ Transplants
      • Shift from Traditional Serological Typing to Gene-based HLA Typing

CHAPTER 4 - TRANSPLANT DIAGNOSTICS MARKET ANALYSIS BY TECHNOLOGIES

  • TABLE 27: GLOBAL MARKET FOR TRANSPLANT DIAGNOSTICS BY TECHNOLOGIES, THROUGH 2021 ($ MILLIONS)
  • MOLECULAR ASSAY TECHNOLOGIES
    • TABLE 28: GLOBAL MARKET FOR MOLECULAR ASSAYS BY TYPE, THROUGH 2021 ($ MILLIONS)
    • TABLE 29: GLOBAL MARKET FOR MOLECULAR ASSAY BY REGION, THROUGH 2021 ($ MILLIONS)
  • PCR-BASED MOLECULAR ASSAY
    • TABLE 30: GLOBAL MARKET FOR PCR-BASED MOLECULAR ASSAYS BY REGION, THROUGH 2021 ($ MILLIONS)
    • FIGURE 34: WORKFLOW FOR POLYMERASE CHAIN REACTION
    • PCR-Sequence Specific Primer (SSP)
    • PCR Sequence-Specific Oligonucleotide (SSO)
  • SEQUENCING-BASED MOLECULAR ASSAY
    • TABLE 31: GLOBAL MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS BY REGION, THROUGH 2021 ($ MILLIONS)
    • Sanger Sequencing
    • Next-Generation Sequencing
      • TABLE 32: COMPARISON OF NGS PLATFORMS
  • NONMOLECULAR ASSAY TECHNOLOGIES
    • TABLE 33: GLOBAL MARKET FOR NONMOLECULAR ASSAYS BY TYPE, THROUGH 2021 ($ MILLIONS)
    • TABLE 34: GLOBAL MARKET FOR NONMOLECULAR ASSAYS BY REGION, THROUGH 2021 ($ MILLIONS)
  • SEROLOGICAL ASSAYS
    • TABLE 35: GLOBAL MARKET FOR SEROLOGICAL ASSAYS BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 36: SEROLOGICAL TYPES AND THEIR SENSTIVITY FOR ANTIBODY DETECTION (MCG/ML)
  • MIXED LYMPHOCYTE CULTURE ASSAYS
    • TABLE 37: GLOBAL MARKET FOR MLC ASSAYS, BY REGION, THROUGH 2021 ($ MILLIONS)

CHAPTER 5 - BY COMPONENT

  • TABLE 38: GLOBAL TRANSPLANT DIAGNOSTICS MARKET BY COMPONENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 39: GLOBAL TRANSPLANT DIAGNOSTICS COMPONENT MARKET BY REGION, THROUGH 2021 ($ MILLIONS)
  • INSTRUMENTS
    • TABLE 40: GLOBAL TRANSPLANT DIAGNOSTICS INSTRUMENTS MARKET BY REGION, THROUGH 2021 ($ MILLIONS)
    • SEQUENCING SYSTEMS
    • READER/ANALYZER INSTRUMENTS
    • AUTOMATED DISPENSERS
    • NGS INSTRUMENTS
      • TABLE 41: LIST OF FEW COMMERCIALLY AVAILABLE INSTRUMENTS FOR TRANSPLANT DIAGNOSTICS
    • REAGENTS AND CONSUMABLES
      • TABLE 42: GLOBAL TRANSPLANT DIAGNOSTICS REAGENTS AND CONSUMABLES MARKET BY REGION, THROUGH 2021 ($ MILLIONS)
    • CYTOTOXIC CONTROLS
    • B27 MONOCLONAL ANTIBODIES
    • BULK MONOCLONAL ANTIBODIES
    • FLUOROBEADS ISOLATION REAGENTS
    • STAINING/QUENCHING REAGENTS
    • ISOLATION REAGENTS
    • POOLED HUMAN SERUM (PHS)
    • RABBIT COMPLEMENT
    • STAIN-FIXATION REAGENTS
    • SEROLOGICAL TYPING REAGENTS FOR HLA TYPING
      • TABLE 43: LIST OF COMMERCIALLY AVAILABLE REAGENTS FOR TRANSPLANT DIAGNOSTICS
    • SOFTWARE AND SERVICES
      • TABLE 44: GLOBAL TRANSPLANT DIAGNOSTICS SOFTWARE AND SERVICES MARKET BY REGION, THROUGH 2021 ($ MILLIONS)
      • TABLE 45: LIST OF COMMERCIALLY AVAILABLE SOFTWARE AND SERVICES FOR TRANSPLANT DIAGNOSTICS

CHAPTER 6 - TRANSPLANT DIAGNOSTICS MARKET ANALYSIS BY END USER

  • TABLE 46: GLOBAL TRANSPLANT DIAGNOSTICS MARKET BY END USER, THROUGH 2021 ($ MILLIONS)
  • TABLE 47: GLOBAL TRANSPLANT DIAGNOSTICS MARKET BY REGION, THROUGH 2021 ($ MILLIONS)
  • HOSPITALS AND TRANSPLANT CENTERS
    • TABLE 48: GLOBAL TRANSPLANT DIAGNOSTICS HOSPITALS AND TRANSPLANT CENTERS MARKET BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 49: HOSPITALS PROVIDING HLA TYPING AND TRANSPLANT SERVICES
  • RESEARCH LABORATORIES AND ACADEMIC INSTITUTIONS
    • TABLE 50: GLOBAL TRANSPLANT DIAGNOSTICS RESEARCH LABORATORIES AND ACADEMIC INSTITUTIONS MARKET BY REGION, THROUGH 2021 ($ MILLIONS)
  • COMMERCIAL SERVICE PROVIDERS
    • TABLE 51: GLOBAL TRANSPLANT DIAGNOSTICS COMMERCIAL SERVICE PROVIDERS MARKET BY REGION, THROUGH 2021 ($ MILLIONS)

CHAPTER 7 - TRANSPLANT DIAGNOSTICS MARKET ANALYSIS BY APPLICATIONS

  • TABLE 52: GLOBAL TRANSPLANT DIAGNOSTICS MARKET BY APPLICATIONS, THROUGH 2021 ($ MILLIONS)
  • TABLE 53: GLOBAL TRANSPLANT DIAGNOSTICS MARKET BY REGION, THROUGH 2021 ($ MILLIONS)
  • RESEARCH
    • TABLE 54: GLOBAL TRANSPLANT DIAGNOSTICS RESEARCH MARKET BY REGION, THROUGH 2021 ($ MILLIONS)
  • BLOOD AND MARROW TRANSPLANT PROGRAMS
    • HEART/LUNG TRANSPLANTATION
      • TABLE 55: SURVIVAL RATES OF PATIENTS
    • DIAGNOSTICS
      • TABLE 56: GLOBAL TRANSPLANT DIAGNOSTICS MARKET BY REGION, THROUGH 2021 ($ MILLIONS)

CHAPTER 8 - COMPETITIVE LANDSCAPE

  • COMPETITIVE LANDSCAPE
    • TABLE 57: KEY COMPETITIVE STRATEGIES, 2012-2016 (NO./%)
  • PRODUCT APPROVALS AND LAUNCHES
    • TABLE 58: PRODUCT APPROVAL AND LAUNCH STRATEGY BY COMPANY, 2013-2016 (NO./%)
    • TABLE 59: LIST OF KEY PRODUCT APPROVALS AND LAUNCHES ANNOUNCED, 2013-2016
  • MERGERS AND ACQUISITIONS
    • TABLE 60: MERGER AND ACQUISITION STRATEGY BY COMPANIES, 2012-2016 (NO./%)
    • TABLE 61: LIST OF KEY MERGERS AND ACQUISITIONS ANNOUNCED, 2013-2016
  • AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS
    • TABLE 62: AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS STRATEGY BY COMPANIES, 2012-2016 (NO./%)
    • TABLE 63: LIST OF KEY AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS ANNOUNCED, 2012-2016
  • EXPANSION
    • TABLE 64: EXPANSION STRATEGIES BY COMPANIES, 2011-2016 (NO./%)
    • TABLE 65: LIST OF KEY EXPANSIONS ANNOUNCED, 2011-2016
  • INVESTMENTS
    • TABLE 66: INVESTMENTS STRATEGY BY COMPANIES, 2012-2016 (NO./%)
    • TABLE 67: LIST OF KEY INVESTMENTS ANNOUNCED, 2012-2016

CHAPTER 9 - REGIONAL ANALYSIS

  • TABLE 68: GLOBAL TRANSPLANT DIAGNOSTICS MARKET BY REGION, THROUGH 2021 ($ MILLIONS)
  • NORTH AMERICA
    • TABLE 69: NORTH AMERICAN TRANSPLANT DIAGNOSTIC MARKET BY COUNTRY, THROUGH 2021 ($ MILLIONS)
    • TABLE 70: NORTH AMERICAN TRANSPLANT DIAGNOSTIC MARKET BY END USER, THROUGH 2021 ($ MILLIONS)
    • TABLE 71: COMMERCIAL TRANSPLANT DIAGNOSTICS PRODUCTS APPROVED BY THE FDA
    • TABLE 72: MAJOR TRANSPLANT DIAGNOSTICS COMPANIES BASED IN THE UNITED STATES
  • EUROPE
    • TABLE 73: EUROPEAN TRANSPLANT DIAGNOSTIC MARKET BY COUNTRY, THROUGH 2021 ($ MILLIONS)
    • TABLE 74: EUROPEAN TRANSPLANT DIAGNOSTIC MARKET BY END USER, THROUGH 2021 ($ MILLIONS)
  • SPAIN
    • TABLE 75: NUMBER OF ORGAN DONATIONS IN SPAIN BY TYPE OF DONOR, 2014
    • TABLE 76: NUMBER OF ORGAN TRANSPLANTS IN SPAIN BY TYPE OF ORGAN, 2014
  • ITALY
    • TABLE 77: NUMBER OF ORGAN TRANSPLANTS IN ITALY BY TYPE OF ORGAN, 2015
    • TABLE 78: NUMBER OF ORGAN DONATIONS IN ITALY BY TYPE OF DONOR, 2015
  • TURKEY
    • TABLE 79: NUMBER OF ORGAN DONATIONS IN TURKEY BY TYPE OF DONOR, 2015
    • TABLE 80: NUMBER OF ORGAN TRANSPLANTS IN TURKEY BY TYPE OF ORGAN, 2015
    • TABLE 81: CE APPROVAL FOR TRANSPLANT DIAGNOSTICS MARKET
    • TABLE 82: MAJOR EUROPEAN PLAYERS IN TRANSPLANT DIAGNOSTICS MARKET
  • ASIA-PACIFIC
    • TABLE 83: ASIA-PACIFIC TRANSPLANT DIAGNOSTIC MARKET BY COUNTRY, THROUGH 2021 ($ MILLIONS)
    • TABLE 84: ASIA-PACIFIC TRANSPLANT DIAGNOSTIC MARKET BY END USER, THROUGH 2021 ($ MILLIONS)
  • MALAYSIA
    • TABLE 85: NUMBER OF ORGAN DONATIONS IN MALAYSIA BY TYPE OF DONOR, 2013
    • TABLE 86: NUMBER OF ORGAN TRANSPLANTS IN MALAYSIA BY TYPE OF ORGAN, 2013
  • NEW ZEALAND
    • TABLE 87: NUMBER OF ORGAN DONATIONS IN NEW ZEALAND BY TYPE OF DONOR, 2015
    • TABLE 88: NUMBER OF ORGAN TRANSPLANT PROCEDURES IN NEW ZEALAND BY TYPE OF ORGAN, 2015
    • TABLE 89: TRANSPLANT DIAGNOSTICS COMPANY PRESENT IN ASIA
  • REST OF THE WORLD
    • TABLE 90: ROW TRANSPLANT DIAGNOSTICS MARKET BY COUNTRY, THROUGH 2021 ($ MILLIONS)
    • TABLE 91: ROW TRANSPLANT DIAGNOSTICS MARKET BY END USER, THROUGH 2021 ($ MILLIONS)
  • BRAZIL
    • TABLE 92: COMMUNICABLE AND NONCOMMUNICABLE DISEASES LEADING TO MORTALITY IN BRAZIL, 2014 (%)
    • TABLE 93: NUMBER OF ORGAN DONATIONS IN BRAZIL BY TYPE OF DONOR, 2015
    • TABLE 94: NUMBER OF ORGAN TRANSPLANT PROCEDURES IN BRAZIL BY TYPE OF ORGAN, 2015
  • ISRAEL
    • TABLE 95: AGE ADJUSTED HOSPITALIZATION RATE DUE TO CHRONIC DISEASES IN ISRAEL, 2013 (PER 100,000 ABOVE 15 YEARS)
    • TABLE 96: NUMBER OF ORGAN TRANSPLANT PROCEDURES IN ISRAEL BY TYPE OF ORGAN, 2015
    • TABLE 97: NUMBER OF ORGAN TRANSPLANT PROCEDURES IN ISRAEL BY TYPE OF ORGAN, 2015
  • IRAN
    • TABLE 98: NUMBER OF ORGAN DONATIONS IN IRAN BY TYPE OF DONOR, 2015
    • TABLE 99: NUMBER OF ORGAN TRANSPLANT PROCEDURES IN IRAN BY TYPE OF ORGAN, 2015
    • TABLE 100: NUMBER OF TISSUE TRANSPLANT PROCEDURES IN IRAN BY TYPE OF TISSUE, 2015
  • SAUDI ARABIA
    • TABLE 101: NUMBER OF ORGAN DONATIONS IN SAUDI ARABIA BY TYPE OF DONOR, 2015
    • TABLE 102: NUMBER OF ORGAN TRANSPLANT PROCEDURES IN SAUDI ARABIA BY TYPE OF ORGAN, 2015

CHAPTER 10 - PATENT ANALYSIS

  • INTRODUCTION
    • TABLE 103: PATENTS REGISTERED/APPROVED BY COUNTRY, 2010-2016 (NO./%)
    • FIGURE 35: PATENTS REGISTERED/APPROVED BY COUNTRY, 2010-2016 (%)
  • UNITED STATES
    • TABLE 104: PATENTS REGISTERED/APPROVED IN U.S. BY TYPE OF PRODUCT, 2010-2016 (NO./%)
    • FIGURE 36: PATENTS REGISTERED/APPROVED IN U.S. BY TYPE OF PRODUCT, 2010-2016 (%)
  • CHINA
    • TABLE 105: PATENTS REGISTERED/APPROVED IN CHINA BY TYPE OF PRODUCT, 2010-2016 (NO./%)
    • FIGURE 37: PATENTS REGISTERED/APPROVED IN CHINA BY TYPE OF PRODUCT, 2010-2016 (%)
  • EUROPE
    • TABLE 106: PATENTS REGISTERED/APPROVED BY MARKET PARTICIPANTS, 2010-2016 (NO./%)
    • TABLE 107: PATENTS REGISTERED/APPROVED BY MARKET PARTICIPANTS, 2010-2016
    • FIGURE 38: PATENTS REGISTERED/APPROVED BY MARKET PARTICIPANTS, 2010-2016 (%)
    • TABLE 108: PATENTS REGISTERED/APPROVED BY TYPE OF PRODUCT, 2010-2016 (NO./%)
    • FIGURE 39: PATENTS REGISTERED/APPROVED BY TYPE OF PRODUCT, 2010-2016 (%)
    • TABLE 109: PATENTS RELATED TO TRANSPLANTS

CHAPTER 11 - COMPANY PROFILES

  • ABBOTT LABORATORIES
    • TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO
    • RECENT DEVELOPMENTS
      • TABLE 110: RECENT DEVELOPMENTS OF ABBOTT LABORATORIES
    • ABBOTT LABORATORIES FINANCIALS
      • TABLE 111: ABBOTT LABORATORIES FINANCIALS, 2013-2015 ($ MILLIONS/%)
  • AFFYMETRIX INC.
    • TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO
    • RECENT DEVELOPMENTS
      • TABLE 112: RECENT DEVELOPMENTS OF AFFYMETRIX INC.
    • AFFYMETRIX INC. FINANCIALS
      • TABLE 113: AFFYMETRIX INC. FINANCIALS, 2012-2014 ($ MILLIONS/%)
  • ASTELLAS PHARMA INC.
    • TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO
    • ASTELLAS PHARMA INC. FINANCIALS
      • TABLE 114: ASTELLAS PHARMA INC. FINANCIALS, 2013-2015 ($ MILLIONS/%)
  • BIOFORTUNA LTD.
    • TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO
    • RECENT DEVELOPMENTS
      • TABLE 115: RECENT DEVELOPMENTS OF BIOFORTUNA LTD.
    • BIOFORTUNA LTD. FINANCIALS
      • TABLE 116: BIOFORTUNA LTD. FINANCIALS, 2013-2015 ($ MILLIONS/%)
  • BIO-RAD LABORATORIES
    • TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO
    • RECENT DEVELOPMENTS
      • TABLE 117: RECENT DEVELOPMENTS OF BIO-RAD LABORATORIES
    • BIO-RAD LABORATORIES FINANCIALS
      • TABLE 118: BIO-RAD LABORATORIES FINANCIALS, 2013-2015 ($ MILLIONS/%)
  • CAREDX INC.
    • TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO
    • RECENT DEVELOPMENTS
      • TABLE 119: RECENT DEVELOPMENTS OF CAREDX INC.
    • CAREDX INC. FINANCIALS
      • TABLE 120: CAREDX INC. FINANCIALS, 2012-2014 ($ MILLIONS/%)
  • DIASORIN S.P.A.
    • TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO
    • RECENT DEVELOPMENTS
      • TABLE 121: RECENT DEVELOPMENTS OF DIASORIN S.P.A.
    • FINANCIALS
      • TABLE 122: DIASORIN S.P.A. FINANCIALS, 2013-2015 ($ MILLIONS/%)
  • F. HOFFMANN-LA ROCHE AG
    • TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO
    • RECENT DEVELOPMENTS
      • TABLE 123: RECENT DEVELOPMENTS OF F. HOFFMANN-LA ROCHE AG
    • F. HOFFMANN-LA ROCHE AG FINANCIALS
      • TABLE 124: F. HOFFMANN-LA ROCHE AG FINANCIALS, 2013-2015 ($ MILLIONS/%)
  • FUJIREBIO EUROPE N.V.
    • TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO
    • GENDX (GENOME DIAGNOSTICS B.V.)
    • TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO
    • RECENT DEVELOPMENTS
      • TABLE 125: RECENT DEVELOPMENTS OF GENDX
  • ILLUMINA INC.
    • TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO
    • RECENT DEVELOPMENTS
      • TABLE 126: RECENT DEVELOPMENTS OF ILLUMINA INC.
    • ILLUMINA INC. FINANCIALS
      • TABLE 127: ILLUMINA INC. FINANCIALS, 2013-2015 ($ MILLIONS/%)
  • IMMUCOR INC.
    • TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO
    • RECENT DEVELOPMENTS
      • TABLE 128: RECENT DEVELOPMENTS OF IMMUCOR INC.
    • IMMUCOR INC. FINANCIALS
      • TABLE 129: IMMUCOR INC. FINANCIALS, 2013-2015 ($ MILLIONS/%)
  • LINKAGE BIOSCIENCES
    • TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO
    • RECENT DEVELOPMENTS
      • TABLE 130: RECENT DEVELOPMENTS OF LINKAGE BIOSCIENCES
  • LUMINEX CORP.
    • TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO
    • RECENT DEVELOPMENTS
      • TABLE 131: RECENT DEVELOPMENTS OF LUMINEX CORP.
    • LUMINEX CORP. FINANCIALS
      • TABLE 132: LUMINEX CORP. FINANCIALS, 2013-2015 ($ MILLIONS/%)
  • OLERUP SSP AB
    • TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO
    • RECENT DEVELOPMENTS
      • TABLE 133: RECENT DEVELOPMENTS OF OLERUP SSP AB
  • OMIXON BIOCOMPUTING LTD.
    • TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO
    • QIAGEN N.V.
    • TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO
    • RECENT DEVELOPMENTS
      • TABLE 134: RECENT DEVELOPMENTS OF QIAGEN N.V.
    • QIAGEN N.V. FINANCIALS
      • TABLE 135: QIAGEN N.V. FINANCIALS, 2013-2015 ($ MILLIONS/%)
  • SIGMA-ALDRICH CORP.
    • TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO
    • SIGMA-ALDRICH FINANCIALS
      • TABLE 136: SIGMA-ALDRICH FINANCIALS, 2013-2015 ($ MILLIONS/%)
  • THERMO FISHER SCIENTIFIC INC.
    • TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO
    • RECENT DEVELOPMENTS
      • TABLE 137: RECENT DEVELOPMENTS OF THERMO FISHER SCIENTIFIC INC.
    • THERMO FISHER SCIENTIFIC FINANCIALS
      • TABLE 138: THERMO FISHER SCIENTIFIC FINANCIALS, 2013-2015 ($ MILLIONS/%)
  • TRANSPLANT GENOMICS INC.
    • RECENT DEVELOPMENTS
      • TABLE 139: RECENT DEVELOPMENTS OF TRANSPLANT GENOMICS INC.

CHAPTER 12 - APPENDIX

  • TABLE 140: LIST OF PATENTS ISSUED IN CANADA
  • TABLE 141: LIST OF PATENTS ISSUED IN CHINA
  • TABLE 142: LIST OF PATENTS IN ISSUED EUROPE (WO)
  • TABLE 143: LIST OF PATENTS ISSUED IN EUROPE
  • TABLE 144: LIST OF PATENTS ISSUED BY THE EUROPEAN PATENT OFFICE (EPO)
  • TABLE 145: LIST OF PATENTS ISSUED IN JAPAN
  • TABLE 146: LIST OF PATENTS ISSUED IN KOREA
  • TABLE 147: LIST OF PATENTS ISSUED IN THE RUSSIAN FEDERATION
  • TABLE 148: LIST OF PATENTS ISSUED IN SINGAPORE

LIST OF TABLES

  • SUMMARY TABLE GLOBAL MARKET FOR TRANSPLANT DIAGNOSTICS BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 1: TYPES OF ORGAN REJECTION POST-TRANSPLANT PROCEDURES
    • TABLE 2: MAJOR TYPES OF HUMAN LEUKOCYTE ANTIGEN
    • TABLE 3: LIST OF AUTOIMMUNE DISEASES LINKED WITH HLA TYPES
    • TABLE 4: LIST OF FEW HLA TESTS COMMERCIALLY AVAILABLE WITH CLINICAL APPLICATIONS
    • TABLE 5: NUCLEIC ACID TESTS APPROVED BY FDA
    • TABLE 6: LIST OF CPT CODES FOR HLA TYPING WITH SEROLOGICAL TESTING
    • TABLE 7: MAXIMUM FEES FOR PATHOLOGY LABORATORY, ON AND AFTER JANUARY 1, 2015 ($)
    • TABLE 8: LABORATORY-BASED PRE-TRANSPLANTATION BIOMARKERS
    • TABLE 9: LABORATORY-BASED POST-TRANSPLANTATION BIOMARKERS (ACUTE ALLOGRAFT REJECTION)
    • TABLE 10: LABORATORY-BASED POST-TRANSPLANTATION BIOMARKERS (CHRONIC ALLOGRAFT DAMAGE)
    • TABLE 11: LABORATORY-BASED POST-TRANSPLANTATION BIOMARKERS (ALLOGRAFT ACCOMMODATION)
    • TABLE 12: FDA-APPROVED BIOMARKERS
    • TABLE 13: MATERIALS USED FOR BIOPRINTING
    • TABLE 14: APPLICATION OF ORGANOIDS BY TYPE
    • TABLE 15: STRATEGIC DEVELOPMENT IN TRANSPLANT DIAGNOSTICS MARKET, 2012-2016 (NO./%)
    • TABLE 16: FDA APPROVALS FOR TRANSPLANT DIAGNOSTICS PRODUCTS, 2013-2016
    • TABLE 17: CE APPROVALS FOR TRANSPLANT DIAGNOSTICS PRODUCTS, 2013-2016
    • TABLE 18: NEW PRODUCT LAUNCHES IN TRANSPLANT DIAGNOSTICS MARKET, 2013-2016
    • TABLE 19: COMPANIES ADOPTING M &A AS A DEVELOPMENTAL STRATEGY IN TRANSPLANT DIAGNOSTICS MARKET
    • TABLE 20: MERGERS AND ACQUISITIONS IN THE TRANSPLANT DIAGNOSTICS MARKET, 2012-2016
    • TABLE 21: COMPANIES ADOPTING AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS AS A DEVELOPMENTAL STRATEGY IN TRANSPLANT DIAGNOSTICS MARKET, 2012-2016
    • TABLE 22: LIST OF COMPANIES THAT ADOPTED AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS AS KEY STRATEGY, 2012-2016
    • TABLE 23: COMPANIES ADOPTING EXPANSION AS A KEY STRATEGY IN TRANSPLANT DIAGNOSTICS MARKET, 2011-2016
    • TABLE 24: COMPANIES ADOPTING INVESTMENT AS A KEY STRATEGY IN TRANSPLANT DIAGNOSTICS MARKET, 2013-2016
    • TABLE 25: CHRONIC DISEASES LISTED BY THE WHO, 2010-2013
    • TABLE 26: PRODUCT LAUNCHES IN TRANSPLANT DIAGNOSTICS MARKET, 2012-2016
    • TABLE 27: GLOBAL MARKET FOR TRANSPLANT DIAGNOSTICS BY TECHNOLOGIES, THROUGH 2021 ($ MILLIONS)
    • TABLE 28: GLOBAL MARKET FOR MOLECULAR ASSAYS BY TYPE, THROUGH 2021 ($ MILLIONS)
    • TABLE 29: GLOBAL MARKET FOR MOLECULAR ASSAY BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 30: GLOBAL MARKET FOR PCR-BASED MOLECULAR ASSAYS BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 31: GLOBAL MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 32: COMPARISON OF NGS PLATFORMS
    • TABLE 33: GLOBAL MARKET FOR NONMOLECULAR ASSAYS BY TYPE, THROUGH 2021 ($ MILLIONS)
    • TABLE 34: GLOBAL MARKET FOR NONMOLECULAR ASSAYS BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 35: GLOBAL MARKET FOR SEROLOGICAL ASSAYS BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 36: SEROLOGICAL TYPES AND THEIR SENSTIVITY FOR ANTIBODY DETECTION (MCG/ML)
    • TABLE 37: GLOBAL MARKET FOR MLC ASSAYS, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 38: GLOBAL TRANSPLANT DIAGNOSTICS MARKET BY COMPONENT, THROUGH 2021 ($ MILLIONS)
    • TABLE 39: GLOBAL TRANSPLANT DIAGNOSTICS COMPONENT MARKET BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 40: GLOBAL TRANSPLANT DIAGNOSTICS INSTRUMENTS MARKET BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 41: LIST OF FEW COMMERCIALLY AVAILABLE INSTRUMENTS FOR TRANSPLANT DIAGNOSTICS
    • TABLE 42: GLOBAL TRANSPLANT DIAGNOSTICS REAGENTS AND CONSUMABLES MARKET BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 43: LIST OF COMMERCIALLY AVAILABLE REAGENTS FOR TRANSPLANT DIAGNOSTICS
    • TABLE 44: GLOBAL TRANSPLANT DIAGNOSTICS SOFTWARE AND SERVICES MARKET BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 45: LIST OF COMMERCIALLY AVAILABLE SOFTWARE AND SERVICES FOR TRANSPLANT DIAGNOSTICS
    • TABLE 46: GLOBAL TRANSPLANT DIAGNOSTICS MARKET BY END USER, THROUGH 2021 ($ MILLIONS)
    • TABLE 47: GLOBAL TRANSPLANT DIAGNOSTICS MARKET BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 48: GLOBAL TRANSPLANT DIAGNOSTICS HOSPITALS AND TRANSPLANT CENTERS MARKET BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 49: HOSPITALS PROVIDING HLA TYPING AND TRANSPLANT SERVICES
    • TABLE 50: GLOBAL TRANSPLANT DIAGNOSTICS RESEARCH LABORATORIES AND ACADEMIC INSTITUTIONS MARKET BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 51: GLOBAL TRANSPLANT DIAGNOSTICS COMMERCIAL SERVICE PROVIDERS MARKET BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 52: GLOBAL TRANSPLANT DIAGNOSTICS MARKET BY APPLICATIONS, THROUGH 2021 ($ MILLIONS)
    • TABLE 53: GLOBAL TRANSPLANT DIAGNOSTICS MARKET BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 54: GLOBAL TRANSPLANT DIAGNOSTICS RESEARCH MARKET BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 55: SURVIVAL RATES OF PATIENTS
    • TABLE 56: GLOBAL TRANSPLANT DIAGNOSTICS MARKET BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 57: KEY COMPETITIVE STRATEGIES, 2012-2016 (NO./%)
    • TABLE 58: PRODUCT APPROVAL AND LAUNCH STRATEGY BY COMPANY, 2013-2016 (NO./%)
    • TABLE 59: LIST OF KEY PRODUCT APPROVALS AND LAUNCHES ANNOUNCED, 2013-2016
    • TABLE 60: MERGER AND ACQUISITION STRATEGY BY COMPANIES, 2012-2016 (NO./%)
    • TABLE 61: LIST OF KEY MERGERS AND ACQUISITIONS ANNOUNCED, 2013-2016
    • TABLE 62: AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS STRATEGY BY COMPANIES, 2012-2016 (NO./%)
    • TABLE 63: LIST OF KEY AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS ANNOUNCED, 2012-2016
    • TABLE 64: EXPANSION STRATEGIES BY COMPANIES, 2011-2016 (NO./%)
    • TABLE 65: LIST OF KEY EXPANSIONS ANNOUNCED, 2011-2016
    • TABLE 66: INVESTMENTS STRATEGY BY COMPANIES, 2012-2016 (NO./%)
    • TABLE 67: LIST OF KEY INVESTMENTS ANNOUNCED, 2012-2016
    • TABLE 68: GLOBAL TRANSPLANT DIAGNOSTICS MARKET BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 69: NORTH AMERICAN TRANSPLANT DIAGNOSTIC MARKET BY COUNTRY, THROUGH 2021 ($ MILLIONS)
    • TABLE 70: NORTH AMERICAN TRANSPLANT DIAGNOSTIC MARKET BY END USER, THROUGH 2021 ($ MILLIONS)
    • TABLE 71: COMMERCIAL TRANSPLANT DIAGNOSTICS PRODUCTS APPROVED BY THE FDA
    • TABLE 72: MAJOR TRANSPLANT DIAGNOSTICS COMPANIES BASED IN THE UNITED STATES
    • TABLE 73: EUROPEAN TRANSPLANT DIAGNOSTIC MARKET BY COUNTRY, THROUGH 2021 ($ MILLIONS)
    • TABLE 74: EUROPEAN TRANSPLANT DIAGNOSTIC MARKET BY END USER, THROUGH 2021 ($ MILLIONS)
    • TABLE 75: NUMBER OF ORGAN DONATIONS IN SPAIN BY TYPE OF DONOR, 2014
    • TABLE 76: NUMBER OF ORGAN TRANSPLANTS IN SPAIN BY TYPE OF ORGAN, 2014
    • TABLE 77: NUMBER OF ORGAN TRANSPLANTS IN ITALY BY TYPE OF ORGAN, 2015
    • TABLE 78: NUMBER OF ORGAN DONATIONS IN ITALY BY TYPE OF DONOR, 2015
    • TABLE 79: NUMBER OF ORGAN DONATIONS IN TURKEY BY TYPE OF DONOR, 2015
    • TABLE 80: NUMBER OF ORGAN TRANSPLANTS IN TURKEY BY TYPE OF ORGAN, 2015
    • TABLE 81: CE APPROVAL FOR TRANSPLANT DIAGNOSTICS MARKET
    • TABLE 82: MAJOR EUROPEAN PLAYERS IN TRANSPLANT DIAGNOSTICS MARKET
    • TABLE 83: ASIA-PACIFIC TRANSPLANT DIAGNOSTIC MARKET BY COUNTRY, THROUGH 2021 ($ MILLIONS)
    • TABLE 84: ASIA-PACIFIC TRANSPLANT DIAGNOSTIC MARKET BY END USER, THROUGH 2021 ($ MILLIONS)
    • TABLE 85: NUMBER OF ORGAN DONATIONS IN MALAYSIA BY TYPE OF DONOR, 2013
    • TABLE 86: NUMBER OF ORGAN TRANSPLANTS IN MALAYSIA BY TYPE OF ORGAN, 2013
    • TABLE 87: NUMBER OF ORGAN DONATIONS IN NEW ZEALAND BY TYPE OF DONOR, 2015
    • TABLE 88: NUMBER OF ORGAN TRANSPLANT PROCEDURES IN NEW ZEALAND BY TYPE OF ORGAN, 2015
    • TABLE 89: TRANSPLANT DIAGNOSTICS COMPANY PRESENT IN ASIA
    • TABLE 90: ROW TRANSPLANT DIAGNOSTICS MARKET BY COUNTRY, THROUGH 2021 ($ MILLIONS)
    • TABLE 91: ROW TRANSPLANT DIAGNOSTICS MARKET BY END USER, THROUGH 2021 ($ MILLIONS)
    • TABLE 92: COMMUNICABLE AND NONCOMMUNICABLE DISEASES LEADING TO MORTALITY IN BRAZIL, 2014 (%)
    • TABLE 93: NUMBER OF ORGAN DONATIONS IN BRAZIL BY TYPE OF DONOR, 2015
    • TABLE 94: NUMBER OF ORGAN TRANSPLANT PROCEDURES IN BRAZIL BY TYPE OF ORGAN, 2015
    • TABLE 95: AGE ADJUSTED HOSPITALIZATION RATE DUE TO CHRONIC DISEASES IN ISRAEL, 2013 (PER 100,000 ABOVE 15 YEARS)
    • TABLE 96: NUMBER OF ORGAN TRANSPLANT PROCEDURES IN ISRAEL BY TYPE OF ORGAN, 2015
    • TABLE 97: NUMBER OF ORGAN TRANSPLANT PROCEDURES IN ISRAEL BY TYPE OF ORGAN, 2015
    • TABLE 98: NUMBER OF ORGAN DONATIONS IN IRAN BY TYPE OF DONOR, 2015
    • TABLE 99: NUMBER OF ORGAN TRANSPLANT PROCEDURES IN IRAN BY TYPE OF ORGAN, 2015
    • TABLE 100: NUMBER OF TISSUE TRANSPLANT PROCEDURES IN IRAN BY TYPE OF TISSUE, 2015
    • TABLE 101: NUMBER OF ORGAN DONATIONS IN SAUDI ARABIA BY TYPE OF DONOR, 2015
    • TABLE 102: NUMBER OF ORGAN TRANSPLANT PROCEDURES IN SAUDI ARABIA BY TYPE OF ORGAN, 2015
    • TABLE 103: PATENTS REGISTERED/APPROVED BY COUNTRY, 2010-2016 (NO./%)
    • TABLE 104: PATENTS REGISTERED/APPROVED IN U.S. BY TYPE OF PRODUCT, 2010-2016 (NO./%)
    • TABLE 105: PATENTS REGISTERED/APPROVED IN CHINA BY TYPE OF PRODUCT, 2010-2016 (NO./%)
    • TABLE 106: PATENTS REGISTERED/APPROVED BY MARKET PARTICIPANTS, 2010-2016 (NO./%)
    • TABLE 107: PATENTS REGISTERED/APPROVED BY MARKET PARTICIPANTS, 2010-2016
    • TABLE 108: PATENTS REGISTERED/APPROVED BY TYPE OF PRODUCT, 2010-2016 (NO./%)
    • TABLE 109: PATENTS RELATED TO TRANSPLANTS
    • TABLE 110: RECENT DEVELOPMENTS OF ABBOTT LABORATORIES
    • TABLE 111: ABBOTT LABORATORIES FINANCIALS, 2013-2015 ($ MILLIONS/%)
    • TABLE 112: RECENT DEVELOPMENTS OF AFFYMETRIX INC.
    • TABLE 113: AFFYMETRIX INC. FINANCIALS, 2012-2014 ($ MILLIONS/%)
    • TABLE 114: ASTELLAS PHARMA INC. FINANCIALS, 2013-2015 ($ MILLIONS/%)
    • TABLE 115: RECENT DEVELOPMENTS OF BIOFORTUNA LTD.
    • TABLE 116: BIOFORTUNA LTD. FINANCIALS, 2013-2015 ($ MILLIONS/%)
    • TABLE 117: RECENT DEVELOPMENTS OF BIO-RAD LABORATORIES
    • TABLE 118: BIO-RAD LABORATORIES FINANCIALS, 2013-2015 ($ MILLIONS/%)
    • TABLE 119: RECENT DEVELOPMENTS OF CAREDX INC.
    • TABLE 120: CAREDX INC. FINANCIALS, 2012-2014 ($ MILLIONS/%)
    • TABLE 121: RECENT DEVELOPMENTS OF DIASORIN S.P.A.
    • TABLE 122: DIASORIN S.P.A. FINANCIALS, 2013-2015 ($ MILLIONS/%)
    • TABLE 123: RECENT DEVELOPMENTS OF F. HOFFMANN-LA ROCHE AG
    • TABLE 124: F. HOFFMANN-LA ROCHE AG FINANCIALS, 2013-2015 ($ MILLIONS/%)
    • TABLE 125: RECENT DEVELOPMENTS OF GENDX
    • TABLE 126: RECENT DEVELOPMENTS OF ILLUMINA INC.
    • TABLE 127: ILLUMINA INC. FINANCIALS, 2013-2015 ($ MILLIONS/%)
    • TABLE 128: RECENT DEVELOPMENTS OF IMMUCOR INC.
    • TABLE 129: IMMUCOR INC. FINANCIALS, 2013-2015 ($ MILLIONS/%)
    • TABLE 130: RECENT DEVELOPMENTS OF LINKAGE BIOSCIENCES
    • TABLE 131: RECENT DEVELOPMENTS OF LUMINEX CORP.
    • TABLE 132: LUMINEX CORP. FINANCIALS, 2013-2015 ($ MILLIONS/%)
    • TABLE 133: RECENT DEVELOPMENTS OF OLERUP SSP AB
    • TABLE 134: RECENT DEVELOPMENTS OF QIAGEN N.V.
    • TABLE 135: QIAGEN N.V. FINANCIALS, 2013-2015 ($ MILLIONS/%)
    • TABLE 136: SIGMA-ALDRICH FINANCIALS, 2013-2015 ($ MILLIONS/%)
    • TABLE 137: RECENT DEVELOPMENTS OF THERMO FISHER SCIENTIFIC INC.
    • TABLE 138: THERMO FISHER SCIENTIFIC FINANCIALS, 2013-2015 ($ MILLIONS/%)
    • TABLE 139: RECENT DEVELOPMENTS OF TRANSPLANT GENOMICS INC.
    • TABLE 140: LIST OF PATENTS ISSUED IN CANADA
    • TABLE 141: LIST OF PATENTS ISSUED IN CHINA
    • TABLE 142: LIST OF PATENTS IN ISSUED EUROPE (WO)
    • TABLE 143: LIST OF PATENTS ISSUED IN EUROPE
    • TABLE 144: LIST OF PATENTS ISSUED BY THE EUROPEAN PATENT OFFICE (EPO)
    • TABLE 145: LIST OF PATENTS ISSUED IN JAPAN
    • TABLE 146: LIST OF PATENTS ISSUED IN KOREA
    • TABLE 147: LIST OF PATENTS ISSUED IN THE RUSSIAN FEDERATION
    • TABLE 148: LIST OF PATENTS ISSUED IN SINGAPORE

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL MARKET FOR TRANSPLANT DIAGNOSTICS BY REGION, 2015-2021 ($ MILLIONS)
    • FIGURE 1: NUMBER OF KIDNEY TRANSPLANTS IN NORTH AMERICA BY COUNTRY, 2015
    • FIGURE 2: NUMBER OF LIVER TRANSPLANTS IN NORTH AMERICA BY COUNTRY, 2015
    • FIGURE 3: NUMBER OF ORGAN DONATIONS IN NORTH AMERICA BY TYPE OF DONOR, 2015
    • FIGURE 4: NUMBER OF TRANSPLANTS BY TYPE OF ORGAN IN U.S., JANUARY 1988-JUNE 2016
    • FIGURE 5: TRANSPLANT PROCEDURES PERFORMED BY ORGAN TYPE IN U.S., JANUARY 1988-JUNE 2016 (%)
    • FIGURE 6: NUMBER OF TRANSPLANTS BY AGE OF RECIPIENT IN U.S., JANUARY 1988-JUNE 2016
    • FIGURE 7: NUMBER OF TRANSPLANTS BY TYPE OF DONOR IN U.S., 2011-2015
    • FIGURE 8: NUMBER OF ORGAN DONATIONS IN U.S. BY TYPE OF DONOR, 2015
    • FIGURE 9: NUMBER OF ORGAN TRANSPLANT PROCEDURES IN U.S. BY TYPE OF ORGAN, 2015
    • FIGURE 10: NUMBER OF ORGAN DONATIONS IN CANADA BY TYPE OF DONOR, 2015
    • FIGURE 11: NUMBER OF ORGAN TRANSPLANT PROCEDURES IN CANADA BY TYPE OF ORGAN, 2015
    • FIGURE 12: NUMBER OF ORGAN DONATIONS IN MEXICO BY TYPE OF DONOR, 2015
    • FIGURE 13: NUMBER OF ORGAN TRANSPLANT PROCEDURES IN MEXICO BY TYPE OF ORGAN, 2015
    • FIGURE 14: NUMBER OF KIDNEY TRANSPLANTS IN EUROPE BY COUNTRY, 2015
    • FIGURE 15: NUMBER OF LIVER TRANSPLANTS IN EUROPE BY COUNTRY, 2015
    • FIGURE 16: NUMBER OF ORGAN DONATIONS IN EUROPE BY TYPE OF DONOR, 2015
    • FIGURE 17: HYPERTENSIVE DISEASES IN EUROPE BY COUNTRY, 2015 (%)
    • FIGURE 18: NUMBER OF DEATHS CAUSED BY CIRCULATORY SYSTEM DISEASES IN EUROPE BY COUNTRY, 2012 (%)
    • FIGURE 19: NUMBER OF ORGAN DONATIONS BY TYPE OF DONOR IN EUROPE (FRANCE, GERMANY AND UNITED KINGDOM), JANUARY 1988-JUNE 2016
    • FIGURE 20: NUMBER OF TRANSPLANT PROCEDURES BY TYPE OF ORGAN IN EUROPE (FRANCE, GERMANY AND UNITED KINGDOM), JANUARY 1988-JUNE 2016
    • FIGURE 21: NUMBER OF KIDNEY TRANSPLANTS IN ASIA-PACIFIC BY COUNTRY, 2015
    • FIGURE 22: NUMBER OF LIVER TRANSPLANTS IN ASIA-PACIFIC BY COUNTRY, 2015
    • FIGURE 23: NUMBER OF LIVER TRANSPLANTS IN ASIA-PACIFIC BY COUNTRY AND TYPE OF DONOR, 2015
    • FIGURE 24: NUMBER OF ORGAN/TISSUE TRANSPLANT PROCEDURES BY TYPE OF DONOR IN HONG KONG, 2015
    • FIGURE 25: NUMBER OF ORGAN TRANSPLANTS FROM DECEASED DONORS BY TYPE OF ORGAN IN JAPAN, 2015
    • FIGURE 26: NUMBER OF ORGAN DONATIONS BY TYPE OF DONOR IN AUSTRALIA, 2015
    • FIGURE 27: NUMBER OF ORGAN TRANSPLANTS BY TYPE OF ORGAN IN AUSTRALIA, 2015
    • FIGURE 28: NUMBER OF TISSUE TRANSPLANT PROCEDURES BY TYPE OF TISSUE IN AUSTRALIA, 2015
    • FIGURE 29: HISTORY OF THE HOPE ACT, 2013
    • FIGURE 30: MAJOR STRATEGIES ADOPTED BY PLAYERS IN THE TRANSPLANT DIAGNOSTICS MARKET
    • FIGURE 31: GLOBAL POPULATION AGED 60 AND OVER BY REGION, 2015 (NO.)
    • FIGURE 32: WAITING LIST FOR ORGANS IN U.S. BY TYPE OF ORGAN AS OF JULY 15, 2016 (NO.)
    • FIGURE 33: WAITING LIST FOR ORGANS IN U.S. BY AGE OF DONOR AS OF JULY 15, 2016 (NO.)
    • FIGURE 34: WORKFLOW FOR POLYMERASE CHAIN REACTION
    • FIGURE 35: PATENTS REGISTERED/APPROVED BY COUNTRY, 2010-2016 (%)
    • FIGURE 36: PATENTS REGISTERED/APPROVED IN U.S. BY TYPE OF PRODUCT, 2010-2016 (%)
    • FIGURE 37: PATENTS REGISTERED/APPROVED IN CHINA BY TYPE OF PRODUCT, 2010-2016 (%)
    • FIGURE 38: PATENTS REGISTERED/APPROVED BY MARKET PARTICIPANTS, 2010-2016 (%)
    • FIGURE 39: PATENTS REGISTERED/APPROVED BY TYPE OF PRODUCT, 2010-2016 (%)
Back to Top